Developed in the labs of Professors Eric Anslyn and Edward Marcotte at the University of Texas at Austin, Erisyon’s technology is the result of nearly a decade of development in an effort to bring the sensitivity, throughput, and scalability of Next Generation DNA sequencing to proteomics.
The result is a solution whose features and advantages include:
Unleashing these capabilities will generate a new era of proteomics research, enabling applications from safer, more personalized medical interventions to more robust, adaptable crops for a changing world.
Erisyon is introducing the world’s first single molecule protein sequencer that provides revolutionary sensitivity and throughput in a cost-effective and user friendly instrument. Combining robust and scalable solutions from analytical and organic chemistry, advanced optics, and bleeding edge computer science, Erisyon enables proteomics without compromises.
Working at the natural limit of a single molecule, Erisyon provides unprecedented sensitivity and resolution that is 1,000,000 times more sensitive than mass spectrometry, the current gold standard for protein analysis. Individual peptides are analyzed to identify and differentiate proteins regardless of abundance. Further, it enables the ability to determine the positions and numbers of post-translationally modified amino acids, even if the case of sequential PTMs.
By adopting the massively parallel architecture of Next Generation DNA sequencing where individual peptide molecules are immobilized on a surface, Erisyon achieves throughputs that are unimaginable using even today’s state of the art methods. Scaleable to at least 1 billion individual peptides measurements, the solution promises to enable single cell proteomics and the evaluation of complex mixtures from bodily serums.
With single molecule resolution for protein identification, Erisyon enables direct quantification of the proteins. This capability improves upon the current industry standard approach of either using relative calibration standards in Mass spec or using RNA expression profiling profiling by providing a direct count of the number of each protein available in a sample.
By combining single molecule sensitivity with massively parallel sequencing, Erisyon allows for evaluating proteins across a wide dynamic range. Complex mixtures can be evaluated across large orders of magnitude. A single protein molecule has as much of a chance as being identified as a million copy of another abundant protein molecule.
Capable of working at sample concentrations of a zeptomole (10-21 of a mole or about 600 molecules), Erisyon permits discovery and analysis of proteins that are typically lost in other techniques. For instance, recovering and evaluating important proteins from tumor samples can enable doctors to more effectively produce personalized therapies for cancer that are more tolerable and effective.
Taking advantage of the latest developments in machine learning and bioinformatics enables Erisyon to produce actionable results quickly and accurately. Erisyon’s informatics streamlines the entire sequencing process, from optimizing upstream sample preparation to accurately performing downstream sequence identification.
Molecular biomarkers are gauges that provide insights into the health of a patient. Biomarkers are the key indicators in to measure the progression of chronic diseases, liquid biopsies for cancer, and companion diagnostics to improve therapeutic outcomes. The technology’s single molecule sensitivity and high throughput enables a new landscape of biomarker applications with its ability to isolate and measure serum-based biomarkers whose concentrations are well below the sensitivity of existing techniques.
Cancer is a complex, rapidly changing disease that emerges from mutations in the patient’s genome. However, the therapeutic targets of drugs, whether it’s a small molecule, anti-body, or immunotherapy, are proteins. With a resolution and sensitivity that is orders of magnitudes better than existing tools, Erisyon will enable new discoveries about the nature of cancer, leading safer and more personalized therapies.
Plant’s response to stress through the addition or alteration of existing proteins through post translational modifications (PTMs) to regulate metabolism or enable inter- or intra cell signaling. The Erisyon technology’s ability to elucidate PTMs, particularly phosphorylation, is a powerful tool in understanding how to breed better crops in order to withstand stress like biological pathogens or drought.
Proteins are the targets of the majority of drugs in development today, whether those drugs are small molecules or biologics. However, the process of understanding of how those drugs interact with the protein is time consuming, laborious, and often inconclusive. With Erisyon ability to determine the precise positions of post-translational modifications and the reactive amino acids on a molecule by molecule basis, an entirely new way of understanding drug interactions can be achieved
Enzymes is increasingly being applied to improve all areas from making our water safer to our clothes cleaner. These catalytic proteins are environmentally friendly and more efficient than the chemical additives that they replace. With more efficient and precise sequencing, Erisyon can help develop better enzymes for more industrial applications.